These three cell lines thus provided us with reasonable examples to test the effectiveness of adding a FAK tyrosine kinase inhibitor to erlotinib treatment in order to more potently inhibit the growth of EGFR TKI-resistant NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.